Sign inJoin waitlistJoin the waitlist

Elana Jaye Bernstein

Director, Columbia University/New York-Presbyterian Hospital Scleroderma Program · Columbia University/New York-Presbyterian Hospital

Credentials: · · · · ·

History

Columbia University/New York-Presbyterian Hospital Scleroderma Program
Present
Columbia University Vagelos College of Physicians and Surgeons
Present

Hospital for Special Surgery
Until 2013
Massachusetts General Hospital
Until 2010
Massachusetts General Hospital
Until 2008
Mount Sinai School of Medicine
2007
Amherst College
2003

Research

Post-acute COVID-19 syndrome
Review · Nature Medicine · 2021 · 3,389 citations
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune…
Arthritis & Rheumatology · 2024 · 174 citations
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
Arthritis & Rheumatology · 2020 · 174 citations

Dinesh Khanna
42 papers
Jessica Gordon
32 papers
Virginia Steen
31 papers
Shervin Assassi
28 papers
Tracy Frech
28 papers
Ami Shah
23 papers
Robyn Domsic
23 papers
Faye Hant
22 papers
Lorinda Chung
22 papers
VS
Victoria Shanmugam
20 papers
Flavia Castelino
19 papers
Elizabeth Volkmann
17 papers

Grants

Vasculopathy and Systemic Sclerosis-Associated Interstitial Lung Disease
National Heart, Lung, and Blood Institute · R01
Contact PI · $3.5M · Columbia University Health Sciences
2022–2027
Screening Chest CT to Detect Interstitial Lung Disease in Systemic Sclerosis
National Institute of Arthritis and Musculoskeletal and Skin Diseases · K23
Contact PI · $794.1K · Columbia University Health Sciences
2019–2025

Clinical trials

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2024–2029
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Site PI · Recruiting · Phase 2, Phase 3
Cabaletta Bio
2024–2029